MercoPress. South Atlantic News Agency
Tuesday, June 9th 2026 - 07:43 UTC
The vaccine was approved by the regulatory agency ANVISA in late 2025 for people aged 12 to 59, and the campaign began in February with health personnel
Brazil temporarily suspended the dengue vaccination campaign it began in January, after detecting two deaths and several cases of serious adverse reactions. The vaccine, the world's first single-dose shot, was developed by the Butantan Institute in São Paulo and had already been given to half a million people through the public health system. Health authorities stressed that there is not yet enough data to link the deaths to the product and that the interruption is a preventive measure.
In recent months, nearly 4,000 cases were recorded of people with dengue-like symptoms after immunization, something that fell within expectations. The alarm arose from 42 more extreme episodes, with intense abdominal pain, persistent vomiting and bleeding, among them the death of a 48-year-old woman and a 58-year-old man. In all, 501,044 people were vaccinated —mostly health workers in priority regions— and the Health Ministry specified that adverse cases represent 0.0008% of those immunized.
